Precision BioSciences Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 124

Employees

  • Stock Symbol
  • DTIL

Stock Symbol

  • Share Price
  • $12.74
  • (As of Friday Closing)

Precision BioSciences General Information

Description

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 302 East Pettigrew Street
  • Suite A-100
  • Durham, NC 27701
  • United States
+1 (919) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precision BioSciences Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.74 $13.00 $8.25 - $27.00 $88.2M 6.93M 126K -$7.36

Precision BioSciences Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 8,374 (53,872) (52,551) 300,750
Revenue 57,531 48,727 25,098 115,529
EBITDA (26,467) (39,728) (66,267) (20,481)
Net Income (27,671) (61,319) (111,637) (30,602)
Total Assets 184,741 159,781 238,169 211,498
Total Debt 31,053 31,268 24,960 9,113
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Precision BioSciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Precision BioSciences‘s full profile, request access.

Request a free trial

Precision BioSciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Precision BioSciences‘s full profile, request access.

Request a free trial

Precision BioSciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, A
Biotechnology
Durham, NC
124 As of 2024
00000
000000000 00000

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000

000000

x ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate veli
0000 000000000
Cambridge, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precision BioSciences Competitors (65)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Intellia Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
Editas Medicine Formerly VC-backed Cambridge, MA 000 00000 00000000000 00000
Caribou Biosciences Formerly VC-backed Berkeley, CA 000 00000 00000000 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Beam Therapeutics Formerly VC-backed Cambridge, MA 000 00000 000000000 00000
You’re viewing 5 of 65 competitors. Get the full list »

Precision BioSciences Patents

Precision BioSciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3235187-A1 Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency Pending 19-Oct-2021
CA-3235185-A1 Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency Pending 19-Oct-2021
CA-3173051-A1 Engineered meganucleases that target human mitochondrial genomes Pending 22-Apr-2021 00000000
CA-3173245-A1 Engineered meganucleases that target human mitochondrial genomes Pending 22-Apr-2021 00000000
US-20230295590-A1 Engineered meganucleases that target human mitochondrial genomes Active 22-Apr-2021 C12N9/22 0
To view Precision BioSciences’s complete patent history, request access »

Precision BioSciences Executive Team (20)

Name Title Board Seat Contact Info
Michael Amoroso President, Chief Executive Officer & Board Member
Abid Ansari Chief Financial Officer, Finance
Alex Kelly Chief Financial Officer
Juli Blanche Chief People Officer
Jeff Smith Ph.D Chief Re­search Of­fi­cer
You’re viewing 5 of 20 executive team members. Get the full list »

Precision BioSciences Board Members (10)

Name Representing Role Since
Benjamin Belldegrun Aliment Capital Board Observer 000 0000
Geno Germano Self Board Member 000 0000
Kevin Buehler Precision BioSciences Chairman, Chairman of Nominating and Corporate Governance Committee and Member of Audit Committee 000 0000
Michael Amoroso Precision BioSciences President, Chief Executive Officer & Board Member 000 0000
You’re viewing 4 of 10 board members. Get the full list »

Precision BioSciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precision BioSciences ESG

Risk Overview

Risk Rating

Updated July, 02, 2022

27.2 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 443

Rank

00.00

Percentile

To view Precision BioSciences’s complete esg history, request access »

Precision BioSciences FAQs

  • When was Precision BioSciences founded?

    Precision BioSciences was founded in 2006.

  • Who is the founder of Precision BioSciences?

    Matthew Kane, Jeff Smith Ph.D, and Derek Jantz Ph.D are the founders of Precision BioSciences.

  • Who is the CEO of Precision BioSciences?

    Michael Amoroso is the CEO of Precision BioSciences.

  • Where is Precision BioSciences headquartered?

    Precision BioSciences is headquartered in Durham, NC.

  • What is the size of Precision BioSciences?

    Precision BioSciences has 124 total employees.

  • What industry is Precision BioSciences in?

    Precision BioSciences’s primary industry is Biotechnology.

  • Is Precision BioSciences a private or public company?

    Precision BioSciences is a Public company.

  • What is Precision BioSciences’s stock symbol?

    The ticker symbol for Precision BioSciences is DTIL.

  • What is the current stock price of Precision BioSciences?

    As of 24-May-2024 the stock price of Precision BioSciences is $12.74.

  • What is the current market cap of Precision BioSciences?

    The current market capitalization of Precision BioSciences is $88.2M.

  • What is Precision BioSciences’s current revenue?

    The trailing twelve month revenue for Precision BioSciences is $57.5M.

  • Who are Precision BioSciences’s competitors?

    Intellia Therapeutics, Editas Medicine, Caribou Biosciences, CRISPR Therapeutics, and Beam Therapeutics are some of the 65 competitors of Precision BioSciences.

  • What is Precision BioSciences’s annual earnings per share (EPS)?

    Precision BioSciences’s EPS for 12 months was -$7.36.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »